Silverback Therapeutics (NASDAQ:SBTX) Trading Down 1% – Should You Sell?

Silverback Therapeutics, Inc. (NASDAQ:SBTX)’s share price was down 1% during mid-day trading on Tuesday . The stock traded as low as $8.09 and last traded at $8.17. Approximately 3,317,633 shares traded hands during trading, an increase of 882% from the average daily volume of 337,931 shares. The stock had previously closed at $8.25.

Silverback Therapeutics Stock Down 1.7%

The business’s fifty day moving average price is $9.46 and its 200 day moving average price is $9.78. The firm has a market capitalization of $271.88 million, a PE ratio of -3.12 and a beta of 0.60.

About Silverback Therapeutics

Silverback Therapeutics, Inc (NASDAQ: SBTX) is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company’s proprietary ImmunoTAC™ (tumor-activated cytokine) platform is designed to harness the innate immune system by conjugating toll-like receptor agonists to tumor-targeting antibodies. This modular approach aims to deliver immune-activating molecules directly to the tumor microenvironment, potentially improving the safety and efficacy profiles of existing immunomodulatory therapies.

Silverback’s pipeline includes multiple antibody-TLR agonist conjugates in early-phase clinical trials, each directed against distinct tumor-associated antigens.